Skip to main content

Advertisement

SpringerLink
Log in

Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis

  • Genes and Diseases
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

We aimed to investigate whether the PTPRC rs10919563 A/G and Fc gamma receptor 2A (FCGR2A) R131H polymorphisms can predict the response to anti-TNF therapy in rheumatoid arthritis (RA) patients. We conducted a meta-analysis of studies on the association between the PTPRC rs10919563 A/G or the FCGR2A R131H polymorphism and responsiveness to anti-TNF therapy in RA patients. Eighteen studies (twelve on PTPRC and six on FCGR2A) from eight articles involving 3058 patients were considered in this meta-analysis. The meta-analysis showed a significant association between the PTPRC rs10919563 A allele and response to TNF-α blockers in RA. The OR of the PTPRC A allele was significantly lower in responders (OR = 0.584, 95 % CI = 0.409–0.835, P = 0.003). Meta-analysis revealed no association between the FCGR2A HH + HR genotype and responsiveness to TNF blockers in all study subjects (OR = 0.762, 95 % CI = 0.543–1.068, P = 0.115). However, stratification by TNF inhibitor type showed that the FCGR2A HH + HR genotype was associated with responsiveness to adalimumab (OR = 0.591, 95 % CI = 0.369–0.947, P = 0.029), but not infliximab and etanercept (OR = 0.929, 95 % CI = 0.354–2.440, P = 0.881; OR = 0.804, 95 % CI = 0.293–2.207, P = 0.673). The PTPRC rs10919563 A allele shows a poor response to anti-TNF therapy, and the FCGR2A HH + HR genotype shows a poor response to adalimumab for RA. Genotyping for these polymorphisms may be useful for predicting the response to TNF-α blockers with respect to personalized medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Harris ED Jr (1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322(18):1277–1289

    Article  PubMed  Google Scholar 

  2. Choi SJ, Rho YH, Ji JD, Song GG, Lee YH (2006) Genome scan meta-analysis of rheumatoid arthritis. Rheumatology (Oxford) 45(2):166–170

    Article  CAS  Google Scholar 

  3. Brennan FM, Maini RN, Feldmann M (1992) TNF alpha–a pivotal role in rheumatoid arthritis? Br J Rheumatol 31(5):293–298

    Article  CAS  PubMed  Google Scholar 

  4. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C et al (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70(2):266–271

    Article  CAS  PubMed  Google Scholar 

  5. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C et al (2009) Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 41(12):1313–1318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7(11):833–846

    Article  CAS  PubMed  Google Scholar 

  7. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J et al (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum Arthritis Care Res 62(7):1849–1861

    CAS  Google Scholar 

  8. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275–290

    Article  CAS  PubMed  Google Scholar 

  9. Chai L, Song YQ, Leung WK (2012) Genetic polymorphism studies in periodontitis and Fcgamma receptors. J Periodontal Res 47(3):273–285

    Article  CAS  PubMed  Google Scholar 

  10. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK et al (2009) Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 131(2):308–316

    Article  CAS  PubMed  Google Scholar 

  11. Avila-Pedretti G, Tornero J, Fernández-Nebro A, Blanco F, González-Alvaro I, Cañete JD et al (2015) Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis. PLoS One 10(4):e0122088

    Article  PubMed  PubMed Central  Google Scholar 

  12. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR et al (2009) Differences in binding and effector functions between classes of TNF antagonists. Cytokine 45(2):124–131

    Article  CAS  PubMed  Google Scholar 

  13. Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Canete JD, Raya E, Magro-Checa C, et al (2016) Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis. Pharmacogenomics J 16(2):137–140

    Article  CAS  PubMed  Google Scholar 

  14. Zervou MI, Myrthianou E, Flouri I, Plant D, Chlouverakis G, Castro-Giner F et al (2013) Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population. PLoS One 8(9):e74375

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Plant D, Prajapati R, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD et al (2012) Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum 64(3):665–670

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J et al (2010) Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 62(7):1849–1861

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Davila-Fajardo CL, van der Straaten T, Baak-Pablo R, Medarde Caballero C, Cabeza Barrera J, Huizinga TW et al (2015) FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics 16(4):373–381

    Article  CAS  PubMed  Google Scholar 

  18. Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V et al (2014) Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 24(5):238–245

    CAS  PubMed  Google Scholar 

  19. Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R et al (2009) Influence of variants of Fc gamma receptors IIA and IIIA on the American College of rheumatology and european league against rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 68(10):1547–1552

    Article  CAS  PubMed  Google Scholar 

  20. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 27(9):827–833

    Article  CAS  PubMed  Google Scholar 

  21. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG (2011) Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 38(6):3643–3651

    Article  CAS  PubMed  Google Scholar 

  22. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010) Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Mol Biol Rep 37(1):227–234

    Article  CAS  PubMed  Google Scholar 

  23. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558

    Article  PubMed  Google Scholar 

  24. Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315(7121):1533–1537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188

    Article  CAS  PubMed  Google Scholar 

  26. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hermiston ML, Xu Z, Weiss A (2003) CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 21:107–137

    Article  CAS  PubMed  Google Scholar 

  28. Stanford SM, Rapini N, Bottini N (2012) Regulation of TCR signalling by tyrosine phosphatases: from immune homeostasis to autoimmunity. Immunology 137(1):1–19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cooper DN (2010) Functional intronic polymorphisms: buried treasure awaiting discovery within our genes. Hum Genomics 4(5):284–288

    Article  PubMed  PubMed Central  Google Scholar 

  30. Choi SJ, Rho YH, Ji JD, Song GG, Lee YH (2006) Genome scan meta-analysis of rheumatoid arthritis. Rheumatology 45(2):166–170

    Article  CAS  PubMed  Google Scholar 

  31. Tak PP (2012) A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology 51(4):600–609

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Su K, Wu J, Edberg JC, McKenzie SE, Kimberly RP (2002) Genomic organization of classical human low-affinity Fcgamma receptor genes. Genes Immun 3(Suppl 1):S51–S56

    Article  CAS  PubMed  Google Scholar 

  33. Sanders LA, Feldman RG, Voorhorst-Ogink MM, de Haas M, Rijkers GT, Capel PJ et al (1995) Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect Immun 63(1):73–81

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Nimmerjahn F, Ravetch JV (2008) Fcγ receptors as regulators of immune responses. Nat Rev Immunol 8(1):34–47

    Article  CAS  PubMed  Google Scholar 

  35. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y et al (2005) Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 52(1):61–72

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported in part by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI13C2124).

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul, 02841, Korea

    Young Ho Lee

  2. The Hospital for Rheumatic Diseases, Hanyang University Medical Center, Seoul, Korea

    Sang-Cheol Bae

Authors
  1. Young Ho Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sang-Cheol Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Young Ho Lee.

Ethics declarations

Conflict of interest

Young Ho Lee declares no conflict of interest. Sang-Cheol Bae declares no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, Y.H., Bae, SC. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 36, 837–844 (2016). https://doi.org/10.1007/s00296-016-3476-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-016-3476-5

Keywords

Search

Navigation